Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 1/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 1/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 1/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 1/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulindac Sulfide SCHEMBL29536153 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| Sulindac Sulfide SCHEMBL2221399 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| Sulindac Sulfide SCHEMBL2586650 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL15631472 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149218 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL24101275 | 0.91 | PPARG (0.86) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149214 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149223 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL30486787 | 0.91 | PPARG (0.86) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL22109319 | 0.90 | PPARG (0.81) | PPARGCYP1A2MAPTMAPK1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | claimed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | claimed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | claimed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | claimed |
| EP-0206241-B1 | PROCESS FOR THE PREPARATION OF CIS-5-FLUORO-2-METHYL-1-(4-METHYLTHIOBENZYLIDENE)-INDENE-3-ACETIC ACID | ZAMBON S.p.A. (IT) | 1989-04-19 | — | — | EP | claimed |
| US-4748271-A | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methyl-thiobenzylidene)-indene-3-acetic acid | ZAMBON S.P.A. (IT) | 1988-05-31 | — | — | US | claimed |
| EP-0206241-A1 | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid | ZAMBON S.p.A. (IT) | 1986-12-30 | — | — | EP | claimed |
| EP-0036816-B1 | OPHTHALMIC COMPOSITION OF 5-FLUORO-2-METHYL-1-(P-METHYLTHIO-BENZYLIDENE)-3-INDENYLACETIC ACID OR SALT THEREOF | MERCK & CO. INC. (US) | 1985-01-02 | — | — | EP | claimed |
| US-4423074-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylthio)phenyl]me]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | claimed |
| US-4402979-A | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid | Merck & Co., Inc. & Laboratories (US) | 1983-09-06 | — | — | US | claimed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | claimed |
| CN-118853779-A | Preparation method and application of sulindac and intermediate thereof | 江苏暨明医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-01-26 | — | — | US | disclosed |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-07-06 | — | — | US | disclosed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | disclosed |
| US-3970693-A | Process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-07-20 | — | — | US | disclosed |
| US-3944600-A | Indenylidene-3-acetic acid process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | PPARG 1066/4885CYP1A2 877/4885MAPT 4774/4885 |
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | PPARG 599/4885CYP1A2 4577/4885MAPT 1243/4885 |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | PPARG 832/4885CYP1A2 719/4885MAPT 1548/4885 |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | STS, MPST, SULT2A1 | PPARG 151/4885CYP1A2 402/4885MAPT 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.